{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dai X"],"funding":["National Natural Science Foundation of China"],"pagination":["2500221"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12412604"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(9)"],"pubmed_abstract":["Atherosclerosis (AS) is a significant contributor to cardiovascular events. Recent studies have demonstrated that ferroptosis of foam cells is a significant driver of AS. Nevertheless, insights into the precise antiferroptosis therapies remain limited. Here, a multifunctional theranostic nanoplatform is engineered by conjugating folate-modified polydopamine (PDA) nanoparticles (NPs) with L-arginine (FPLG) to inhibit ferroptosis of foam cells. In vitro studies demonstrate that FPLG NPs effectively attenuate ferroptosis in oxidized low-density lipoprotein (ox-LDL)-stimulated macrophages by scavenging reactive oxygen species, upregulating GPX4 and NRF2 activity, and regulating lipid metabolism. In vivo, FPLG NPs exhibit preferential accumulation in atherosclerotic plaques via folate receptors"],"journal":["Small science"],"pubmed_title":["Positron Emission Tomography/Computed Tomography Imaging-Guided Polydopamine Nanoparticles Attenuate Foam Cell Ferroptosis for Targeted Antiatherosclerotic Therapy."],"pmcid":["PMC12412604"],"funding_grant_id":["82441019","82271992"],"pubmed_authors":["Liu X","Yang G","Sheng J","Qi J","Lu G","Lu J","Wang F","Zhang L","Wang Z","Dai X","Xu Y","Zheng T"],"additional_accession":[]},"is_claimable":false,"name":"Positron Emission Tomography/Computed Tomography Imaging-Guided Polydopamine Nanoparticles Attenuate Foam Cell Ferroptosis for Targeted Antiatherosclerotic Therapy.","description":"Atherosclerosis (AS) is a significant contributor to cardiovascular events. Recent studies have demonstrated that ferroptosis of foam cells is a significant driver of AS. Nevertheless, insights into the precise antiferroptosis therapies remain limited. Here, a multifunctional theranostic nanoplatform is engineered by conjugating folate-modified polydopamine (PDA) nanoparticles (NPs) with L-arginine (FPLG) to inhibit ferroptosis of foam cells. In vitro studies demonstrate that FPLG NPs effectively attenuate ferroptosis in oxidized low-density lipoprotein (ox-LDL)-stimulated macrophages by scavenging reactive oxygen species, upregulating GPX4 and NRF2 activity, and regulating lipid metabolism. In vivo, FPLG NPs exhibit preferential accumulation in atherosclerotic plaques via folate receptors","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-01T07:55:23.989Z","creation":"2026-04-08T10:40:54.334Z"},"accession":"S-EPMC12412604","cross_references":{"pubmed":["40917394"],"doi":["10.1002/smsc.202500221"]}}